Pharmacology/Pharmaceutical Industry
Cohort Study: Comparison of rates of Type 2 Diabetes in adults and children treated with anticonvulsant mood stabilizers.
7 Apr, 2022 | 08:32h | UTC
Commentary on Twitter
This cohort study found that the choice of which anticonvulsant mood stabilizer to initiate may have meaningful reductions in type 2 diabetes incidence; valproate was associated with the highest risk and lamotrigine the lowest. https://t.co/pyME0G25wt
— JAMA Network Open (@JAMANetworkOpen) April 6, 2022
Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.
6 Apr, 2022 | 10:59h | UTCProtection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine
Commentary: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (free registration required)
Related:
Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.
U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.
[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
Covid-19: Fourth vaccine doses—who needs them and why?
[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.
Commentary on Twitter
Just published @NEJM
4th dose vaccine protection in >620,000 people vs 3-doses in >620,000, all age 60+, Omicron wave, Israel
—4-fold lower rate of severe disease, no waning at 6 weeks
—2-fold lower rate of infection, rapidly wanedhttps://t.co/g8uGMXGHD6 pic.twitter.com/D7WHywTI1j— Eric Topol (@EricTopol) April 5, 2022
Cohort Study: Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.
6 Apr, 2022 | 10:52h | UTC
Commentary on Twitter
In this cohort study, the incidence rate of #SARSCoV2 infection with Omicron variant was 6 to 8 times that of Delta variant in children younger than 5 years, but severe clinical outcomes were less frequent than with Delta variant. https://t.co/UKiMEznXtX
— JAMA Pediatrics (@JAMAPediatrics) April 1, 2022
M-A: Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives.
6 Apr, 2022 | 10:55h | UTC
RCT: Cabotegravir (intramuscular injections every 8 weeks) for the prevention of HIV-1 in women.
6 Apr, 2022 | 10:51h | UTCCabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial – The Lancet (link to abstract – $ for full-text)
Related:
FDA approves first injectable treatment for HIV pre-exposure prevention.
RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.
Guideline: Revision of pharmacological treatment recommendations for cancer pain.
6 Apr, 2022 | 09:49h | UTC
Review: Antiseizure medications for adults with epilepsy.
6 Apr, 2022 | 10:25h | UTCAntiseizure Medications for Adults With Epilepsy: A Review – JAMA (free for a limited period)
Audio Clinical Review: Epilepsy Diagnosis and Treatment in Adults – JAMA
Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.
5 Apr, 2022 | 09:46h | UTCRelated:
U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.
[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
Covid-19: Fourth vaccine doses—who needs them and why?
[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.
Commentary on Twitter
https://twitter.com/hildabast/status/1509724907965665280
Opinion | Medicinal cannabis for chronic pain: the Bermuda triangle of low-quality studies, countless meta-analyses and conflicting recommendations.
5 Apr, 2022 | 08:52h | UTCRelated:
M-A: Birth outcomes of neonates exposed to marijuana in utero.
Cannabis-related allergies: an international overview and consensus recommendations.
Review: Cannabis-based medicines and medical cannabis for chronic neuropathic pain.
Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain.
Cannabis products are being sold as sleep remedies – here’s the evidence about their effectiveness.
Guideline: Medical cannabis or cannabinoids for chronic pain.
NICE Guideline: Cannabis-Based Medicinal Products
Short Review: Drug Interactions with Cannabinoids
Meta-Analysis: Cannabinoids Not Effective for Cancer-Related Pain
Review: Considerations for cannabinoids in perioperative care by anesthesiologists.
Review: Cannabis-based Medicines and the Perioperative Physician
Perspective: If You Smoke Pot, Your Anesthesiologist Needs To Know
RCT: Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D).
5 Apr, 2022 | 08:50h | UTCInvited Commentary: DNA vaccines join the fight against COVID-19 – The Lancet
Commentary on Twitter
DNA-based #COVID19 vaccine, ZyCoV-D, demonstrates efficacy, safety, and immunogenicity, according to interim analysis of phase 3 trial conducted in India.
More: https://t.co/bI2eXdbOvB pic.twitter.com/tMuHrA1kz6
— The Lancet (@TheLancet) April 2, 2022
Review: Antiplatelet therapy after percutaneous coronary intervention.
5 Apr, 2022 | 08:38h | UTCAntiplatelet therapy after percutaneous coronary intervention – EuroIntervention
Commentary on Twitter
ANTIPLATELET THERAPY AFTER PCI: A State-of-the-Art review that summarises the evidence, and discuss current and future directions of antiplatelet treatment regimens after percutaneous coronary intervention. https://t.co/JyjvRTCz5e pic.twitter.com/T05SVBCmSb
— EuroIntervention (@EuroInterventio) April 1, 2022
#ACC22 – RCT: Tranexamic acid reduces the risk of bleeding in patients undergoing noncardiac surgery.
4 Apr, 2022 | 01:37h | UTCTranexamic Acid in Patients Undergoing Noncardiac Surgery – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery – TCTMD
Commentaries on Twitter
HOT OFF THE PRESS:POISE-3 Tranexamic Acid
Incidence of composite bleeding outcome significantly lower with tranexamic acid vs placebo; between-group difference in composite CV outcome was small, but noninferiority of tranexamic acid was not established.https://t.co/FyuBliD0Mr— Steven Cohn, MD (@preopconsult) April 2, 2022
Among patients undergoing noncardiac surgery, the incidence of the composite bleeding outcome was significantly lower with tranexamic acid than with placebo. #ACC22 https://t.co/cYIQhE7YCD pic.twitter.com/l0QKgpEqnG
— NEJM (@NEJM) April 2, 2022
POISE-3 trial results showed a single dose of tranexamic acid before & after surgery significantly ⬇️ severe bleeding risk in pts undergoing noncardiac surgery compared w/ placebo. Findings could have global 🌏 impact, researchers said. https://t.co/LratgyadtE #ACC22 #cvSurg pic.twitter.com/HXlcp6bb0M
— American College of Cardiology (@ACCinTouch) April 2, 2022
Two new studies show vaccination provides additional protection after Covid-19 infection.
4 Apr, 2022 | 01:16h | UTCCommentaries:
Vaccines offer substantial extra protection after COVID-19 infection – CIDRAP
Had COVID? Getting Vaccine Boosts Resilience Even More, Studies Show – HealthDay
Related:
Commentary on Twitter (thread – click for more)
THREAD | New studies in @TheLancetInfDis confirm #COVID19 vaccines provide extra protection for those with immunity from previous infection, especially against severe disease ⤵️
(Cases of reinfection from omicron variants not included)
— The Lancet (@TheLancet) April 1, 2022
Before-and-after study: Antimicrobial stewardship in high-risk febrile neutropenia patients reduced carbapenem and glycopeptide use and was associated with improved clinical outcomes.
4 Apr, 2022 | 00:49h | UTCRelated:
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines – Annals of Oncology
Commentary from the author on Twitter (thread – click for more)
https://twitter.com/AdrienContejean/status/1508792991917432838
Systematic review: there is insufficient evidence that therapeutic drug monitoring improves outcomes during treatment with penicillins.
4 Apr, 2022 | 00:47h | UTC
RCT: Effect of medical marijuana card ownership on pain, insomnia, and affective disorder symptoms in adults.
1 Apr, 2022 | 10:07h | UTCCommentaries:
Study raises questions about risks of using medical marijuana for mood and anxiety disorders – CNN
Medical Marijuana Rx Ups Odds for Overuse, With No Benefit to Health: Study – HealthDay
Commentary on Twitter
RCT finds medical marijuana cards (MMC) are linked to an increase in cannabis use disorder, with no improvements in pain, depression, and anxiety for adults using medical marijuana but improvements in sleep. https://t.co/0gtGFi1RQ9
— JAMA Network Open (@JAMANetworkOpen) March 18, 2022
RCT: Early treatment with ivermectin does not improve outcomes in patients with Covid-19.
31 Mar, 2022 | 08:41h | UTCCommentary: Ivermectin does not prevent COVID-19 hospitalization, a new study says – NPR
Commentary on Twitter
Ivermectin: the largest randomized, double-blind trial yet conducted, with early treatment, indicates there is no difference compared with placebo. It doesn't work. Period. https://t.co/wiFygjRgkk
just published @NEJM pic.twitter.com/uZ0mMZnO0E— Eric Topol (@EricTopol) March 30, 2022
Meta-analysis of randomized trials: Clopidogrel is better than aspirin for the secondary prevention of cardiovascular events.
31 Mar, 2022 | 08:31h | UTCCommentary: Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention – TCTMD
Commentary on Twitter
Happy to share our paper in @ESC_Journals. In this meta-analysis of randomized trials, we found that as compared with aspirin, P2Y12i was associated with 11% and 19% reduction in MACE and MI respectively. https://t.co/Y3Gstzgfu6
— Devika Aggarwal (@devikagg) March 30, 2022
Case-control study: In children 5 to 11 years of age, the Pfizer vaccine showed an effectiveness of 68% against hospitalization caused by the Omicron variant.
31 Mar, 2022 | 08:37h | UTCCommentary: COVID vaccination of children age 5-11 cut omicron hospitalizations by 68% – Children’s Hospital Boston
Commentary on Twitter
BNT162b2 vaccination reduced the risk of omicron-associated hospitalization by two thirds among children 5 to 11 years of age. https://t.co/mQcchQqbtH pic.twitter.com/Qzy8qKg1wC
— NEJM (@NEJM) March 30, 2022
RCT: Effect of tacrolimus vs. intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis.
31 Mar, 2022 | 08:18h | UTC
Commentary on Twitter
In this RCT, oral tacrolimus was noninferior to intravenous cyclophosphamide for initial therapy of active lupus nephritis, with a more favorable safety profile. https://t.co/scz7lahVRU
— JAMA Network Open (@JAMANetworkOpen) March 30, 2022
Guidance on the need for contraception related to use of pharmaceuticals: providing information on the proper use of pharmaceuticals in patients with reproductive potential.
31 Mar, 2022 | 07:49h | UTC
SEOM clinical guideline: chemotherapy-induced nausea and vomiting.
31 Mar, 2022 | 07:45h | UTCSEOM clinical guideline emesis (2021) – Clinical and Translational Oncology
Related:
Prevention of Chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes.
[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.
30 Mar, 2022 | 10:44h | UTCSecond Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old – Research Square
Commentaries:
Huge Study Finds Second COVID-19 Booster is ‘Life-saving’ for Over 60s – Health Policy Watch
Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly – News Medical
U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.
30 Mar, 2022 | 10:42h | UTCU.S. approves second Covid-19 booster for people 50 and older – STAT
FDA OKs second COVID booster shot for older Americans – CIDRAP
The RECOVERY Trial – two years on.
30 Mar, 2022 | 10:38h | UTCThe RECOVERY Trial – two years on – University of Oxford
Related:
[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19
Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19
Commentary on Twitter
https://twitter.com/MartinLandray/status/1508492188560371717